Herba Siegesbeckiae subfraction HS-C protects against myocardial I/R injury

Announcing a new publication for Acta Materia Medica journal. Herba Siegesbeckiae (HS) has been traditionally used for managing cardio- and cerebro-vascular diseases.

UK vaccine startup Vicebio snags $100M to take on GSK, Pfizer and Moderna

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

September 24, 2024

Samsung Bio inks largest deal yet worth $1.24B with unnamed Asian pharma

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

October 23, 2024

Amgen touts new data for drug MariTide, moving rapidly into Phase 3 work

Amgen said that an interim look at a Phase 2 trial of its anti-obesity drug MariTide had left the company “very encouraged,” and it planned

May 3, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.